drugset / Trial / NCT06767813
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Phase 2
Recruiting
80 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
Timeline
- Start
- 2024-03-19
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | Oral |
| Subject | TQB2868 | Protein / enzyme biologic | — | — |
| Background | Albumin paclitaxel | Unknown | — | — |
| Background | Gemcitabine | Small molecule | — | — |